Warsaw, Poland – June 03, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announces positive interim data from its ongoing Phase 1b trial evaluating nebaprubart, also known as JJP-1212, its investigational potential first-in-class anti-CD89 antagonist, in patients diagnosed with Linear IgA Disease (LAD), a rare autoantibody-mediated skin disease.
Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles....
OTTAWA, Ontario, June 02, 2026 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is proud to announce the recipients of its 2026 Annual Awards, recognizing exceptional leadership and contributions to Canada’s animal health sector.
Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...
Alpha Residential is the recipient of the NAIOP Pittsburgh Best Multifamily Project award for Apex Newbury, the newest multifamily project in South Fayette
Dubai and New York, June 2, 2026 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), today announces the successful closing of a USD 1.4 billion dual-tranche senior unsecured notes offering (the “Offering”) by its subsidiary VEON Midco B.V. (the “Issuer”). The Offering refinances substantially all of VEON’s debt maturing in 2027 ahead of schedule and reflects sustained confidence in VEON’s digital operator transformation and AI1440 strategy.
BEIJING, June 2, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), a leading used car retailer in China, today announced a...